{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-007032","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.618802+00:00","generated_at":"2026-05-24T23:29:03.496521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029","bullets":["FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.","Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.","Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.","MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.","OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-007032","json":"https://secwatch.observer/filing/0001437749-25-007032.json","markdown":"https://secwatch.observer/filing/0001437749-25-007032.md","text":"https://secwatch.observer/filing/0001437749-25-007032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/0001437749-25-007032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/zvra20240918_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:29:03.496521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}